Abstract PO-020: Impact of CDK 4/6i withdrawal or dose adjustment on COVID-19 incidence in HR+/HER2- mBC patients during the pandemic

Pablo Tolosa, Eva Ciruelos, Helena Bote de Cabo et al.|Clinical Cancer Research|2020

Cited by 2